BMS Makes The Case For A Lasting Hematology Legacy
ASH Meeting Will Highlight Key Growth Products
Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.
